Literature DB >> 20109027

Advances in the design and delivery of peptide subunit vaccines with a focus on toll-like receptor agonists.

Matthew Black1, Amanda Trent, Matthew Tirrell, Colleen Olive.   

Abstract

Considerable success has been made with many peptide antigen formulations, and peptide-based vaccines are emerging as the next generation of prophylactic and remedial immunotherapy. However, finding an optimal platform balancing all of the requirements for an effective, specific and safe immune response remains a major challenge for many infectious and chronic diseases. This review outlines how peptide immunogenicity is influenced by the way in which peptides are presented to the immune system, underscoring the need for multifunctional delivery systems that couple antigen and adjuvant into a single construct. Particular attention is given to the ability of Toll-like receptor agonists to act as adjuvants. A survey of recent approaches to developing peptide antigen delivery systems is given, many of which incorporate Toll-like receptor agonists into the design.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20109027      PMCID: PMC2837080          DOI: 10.1586/erv.09.160

Source DB:  PubMed          Journal:  Expert Rev Vaccines        ISSN: 1476-0584            Impact factor:   5.217


  189 in total

Review 1.  Dissecting the role of peptides in the immune response: theory, practice and the application to vaccine design.

Authors:  Anthony W Purcell; Weiguang Zeng; Nicole A Mifsud; Lauren K Ely; Whitney A Macdonald; David C Jackson
Journal:  J Pept Sci       Date:  2003-05       Impact factor: 1.905

2.  Montanide ISA 720 and 51: a new generation of water in oil emulsions as adjuvants for human vaccines.

Authors:  Jerome Aucouturier; L Dupuis; S Deville; S Ascarateil; V Ganne
Journal:  Expert Rev Vaccines       Date:  2002-06       Impact factor: 5.217

3.  Biomimetic design in microparticulate vaccines.

Authors:  Mark E Keegan; Judith A Whittum-Hudson; W Mark Saltzman
Journal:  Biomaterials       Date:  2003-11       Impact factor: 12.479

4.  Size-dependent immunogenicity: therapeutic and protective properties of nano-vaccines against tumors.

Authors:  Theodora Fifis; Anita Gamvrellis; Blessing Crimeen-Irwin; Geoffrey A Pietersz; Jie Li; Patricia L Mottram; Ian F C McKenzie; Magdalena Plebanski
Journal:  J Immunol       Date:  2004-09-01       Impact factor: 5.422

5.  Sequence-specific potent induction of IFN-alpha by short interfering RNA in plasmacytoid dendritic cells through TLR7.

Authors:  Veit Hornung; Margit Guenthner-Biller; Carole Bourquin; Andrea Ablasser; Martin Schlee; Satoshi Uematsu; Anne Noronha; Muthiah Manoharan; Shizuo Akira; Antonin de Fougerolles; Stefan Endres; Gunther Hartmann
Journal:  Nat Med       Date:  2005-02-20       Impact factor: 53.440

Review 6.  Recent advances with TLR2-targeting lipopeptide-based vaccines.

Authors:  Emily M Y Eriksson; David C Jackson
Journal:  Curr Protein Pept Sci       Date:  2007-08       Impact factor: 3.272

Review 7.  Collaboration between the innate immune receptors dectin-1, TLRs, and Nods.

Authors:  David M Underhill
Journal:  Immunol Rev       Date:  2007-10       Impact factor: 12.988

8.  Most lymphoid organ dendritic cell types are phenotypically and functionally immature.

Authors:  Nicholas S Wilson; Dima El-Sukkari; Gabrielle T Belz; Christopher M Smith; Raymond J Steptoe; William R Heath; Ken Shortman; José A Villadangos
Journal:  Blood       Date:  2003-06-05       Impact factor: 22.113

9.  A common pathway mediated through Toll-like receptors leads to T- and natural killer-cell immunosuppression.

Authors:  Ilan Vaknin; Liora Blinder; Lynn Wang; Roi Gazit; Elena Shapira; Olga Genina; Mark Pines; Eli Pikarsky; Michal Baniyash
Journal:  Blood       Date:  2007-11-08       Impact factor: 22.113

10.  GD3 vaccines for melanoma: superior immunogenicity of keyhole limpet hemocyanin conjugate vaccines.

Authors:  F Helling; A Shang; M Calves; S Zhang; S Ren; R K Yu; H F Oettgen; P O Livingston
Journal:  Cancer Res       Date:  1994-01-01       Impact factor: 12.701

View more
  35 in total

Review 1.  Recent progress in adjuvant discovery for peptide-based subunit vaccines.

Authors:  Fazren Azmi; Abdullah Al Hadi Ahmad Fuaad; Mariusz Skwarczynski; Istvan Toth
Journal:  Hum Vaccin Immunother       Date:  2013-12-03       Impact factor: 3.452

2.  Peptide amphiphile micelles self-adjuvant group A streptococcal vaccination.

Authors:  Amanda Trent; Bret D Ulery; Matthew J Black; John C Barrett; Simon Liang; Yulia Kostenko; Natalie A David; Matthew V Tirrell
Journal:  AAPS J       Date:  2014-12-20       Impact factor: 4.009

Review 3.  Recent advances in the production of recombinant subunit vaccines in Pichia pastoris.

Authors:  Man Wang; Shuai Jiang; Yefu Wang
Journal:  Bioengineered       Date:  2016-04       Impact factor: 3.269

4.  Recombinant and epitope-based vaccines on the road to the market and implications for vaccine design and production.

Authors:  Patricio Oyarzún; Bostjan Kobe
Journal:  Hum Vaccin Immunother       Date:  2016-03-03       Impact factor: 3.452

5.  Reduction Sensitive PEG Hydrogels for Codelivery of Antigen and Adjuvant To Induce Potent CTLs.

Authors:  Chintan H Kapadia; Shaomin Tian; Jillian L Perry; J Christopher Luft; Joseph M DeSimone
Journal:  Mol Pharm       Date:  2016-09-22       Impact factor: 4.939

6.  MVA vaccine encoding CMV antigens safely induces durable expansion of CMV-specific T cells in healthy adults.

Authors:  Corinna La Rosa; Jeff Longmate; Joy Martinez; Qiao Zhou; Teodora I Kaltcheva; Weimin Tsai; Jennifer Drake; Mary Carroll; Felix Wussow; Flavia Chiuppesi; Nicola Hardwick; Sanjeet Dadwal; Ibrahim Aldoss; Ryotaro Nakamura; John A Zaia; Don J Diamond
Journal:  Blood       Date:  2016-10-19       Impact factor: 22.113

Review 7.  Supramolecular peptide vaccines: tuning adaptive immunity.

Authors:  Yi Wen; Joel H Collier
Journal:  Curr Opin Immunol       Date:  2015-07-08       Impact factor: 7.486

8.  Adjuvant-Loaded Subcellular Vesicles Derived From Disrupted Cancer Cells for Cancer Vaccination.

Authors:  Alexander S Cheung; Sandeep T Koshy; Alexander G Stafford; Maartje M C Bastings; David J Mooney
Journal:  Small       Date:  2016-03-08       Impact factor: 13.281

9.  pH-Responsive nanoparticle vaccines for dual-delivery of antigens and immunostimulatory oligonucleotides.

Authors:  John T Wilson; Salka Keller; Matthew J Manganiello; Connie Cheng; Chen-Chang Lee; Chinonso Opara; Anthony Convertine; Patrick S Stayton
Journal:  ACS Nano       Date:  2013-04-30       Impact factor: 15.881

10.  Role of T-cell epitope-based vaccine in prophylactic and therapeutic applications.

Authors:  James S Testa; Ramila Philip
Journal:  Future Virol       Date:  2012-11-01       Impact factor: 1.831

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.